两种用药方案治疗食管反流性咽喉炎的疗效比较

Clinical efficacy of anti-reflux therapy combined with tiotropium bromide in COPD patients with GERD

AIM: To investigate the clinical efficacy of anti-reflux therapy combined with tiotropium bromide in chronic obstructive pulmonary disease (COPD) patients with gastroesophageal reflux disease (GERD).

METHODS: Forty-eight GERD patients who were treated at our hospital from January 2014 to December 2014 were included and randomly divided into either an observation group or a control group, with 24 patients in each group. The observation group was given esomeprazole, mosapride and tiotropium bromide, and the control group was only given tiotropium bromide. GERD-Q score, number of acute episodes of COPD and clinical efficacy were compared between the two groups.

RESULTS: After 1 year of treatment, GERD-Q score significantly decreased in the observation group (15.23 ± 3.75 vs 9.83 ± 2.65, P < 0.001), but showed no significant decrease in the control group (14.98 ± 3.64 vs 13.32 ± 3.02, P > 0.05); the number of acute episodes of COPD significantly decreased in both the observation group (1.59 ± 0.34 vs 1.08 ± 0.30) and control group (1.60 ± 0.41 vs 1.33 ± 0.31), and the decrease was more significant in the than observation group than in the control group (1.08 ± 0.30 vs 1.33 ± 0.31, P < 0.01); and the rate of COPD symptom improvement showed no significant difference between the two groups (91.6% vs 87.50%, P > 0.05), but the rate of GERD symptom improvement was better in the observation group (95.83% vs 66.67%, P < 0.01).

CONCLUSION: Anti-reflux treatment combined with tiotropium bromide for COPD patients with GERD is feasible, and it can effectively improve GERD-Q score, decrease the number of acute episodes of COPD and has a significant curative effect.